112 related articles for article (PubMed ID: 24239449)
1. Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma.
Busch J; Seidel C; Goranova I; Erber B; Peters R; Friedersdorff F; Magheli A; Miller K; Grünwald V; Weikert S
Eur J Cancer; 2014 Feb; 50(3):563-9. PubMed ID: 24239449
[TBL] [Abstract][Full Text] [Related]
2. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
3. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
4. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
Iacovelli R; Cartenì G; Sternberg CN; Milella M; Santoni M; Di Lorenzo G; Ortega C; Sabbatini R; Ricotta R; Messina C; Lorusso V; Atzori F; De Vincenzo F; Sacco C; Boccardo F; Valduga F; Massari F; Baldazzi V; Cinieri S; Mosca A; Ruggeri EM; Berruti A; Cerbone L; Procopio G
Eur J Cancer; 2013 Jun; 49(9):2134-42. PubMed ID: 23518211
[TBL] [Abstract][Full Text] [Related]
6. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
[TBL] [Abstract][Full Text] [Related]
8. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Buchler T; Bortlicek Z; Poprach A; Pavlik T; Veskrnova V; Honzirkova M; Zemanova M; Fiala O; Kubackova K; Slaby O; Svoboda M; Vyzula R; Dusek L; Melichar B;
Eur Urol; 2016 Sep; 70(3):469-75. PubMed ID: 26746623
[TBL] [Abstract][Full Text] [Related]
9. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.
Sadeghi S; Albiges L; Wood LS; Black SL; Gilligan TD; Dreicer R; Garcia JA; Escudier BJ; Rini BI
Cancer; 2012 Jul; 118(13):3277-82. PubMed ID: 22139966
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
12. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
[TBL] [Abstract][Full Text] [Related]
13. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium.
Fay AP; Xie WL; Lee JL; Harshman LC; Bjarnason GA; Knox JJ; Ernst S; Wood L; Vaishamayan UN; Yuasa T; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger CK; North SA; Rini BI; Choueiri TK; Heng DY
Clin Genitourin Cancer; 2015 Apr; 13(2):150-5. PubMed ID: 25458371
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
Antoun S; Lanoy E; Iacovelli R; Albiges-Sauvin L; Loriot Y; Merad-Taoufik M; Fizazi K; di Palma M; Baracos VE; Escudier B
Cancer; 2013 Sep; 119(18):3377-84. PubMed ID: 23801109
[TBL] [Abstract][Full Text] [Related]
17. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis.
Ralla B; Erber B; Goranova I; von der Aue L; Floercken A; Hinz S; Kempkensteffen C; Magheli A; Miller K; Busch J
World J Urol; 2016 Aug; 34(8):1147-54. PubMed ID: 26676614
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
Ishihara H; Takagi T; Kondo T; Tachibana H; Yoshida K; Omae K; Iizuka J; Kobayashi H; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):559-567. PubMed ID: 29327159
[TBL] [Abstract][Full Text] [Related]
20. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
